このエントリーをはてなブックマークに追加
ID 47019
フルテキストURL
著者
Nogami, Naoyuki Department of Respiratory Medicine, NHO Shikoku Cancer Center
Hotta, Katsuyuki Department of Respiratory Medicine, Okayama University Hospital
Kuyama, Shoichi Department of Medicine, Chugoku Central Hospital
Kiura, Katsuyuki Department of Respiratory Medicine, Okayama University Hospital
Takigawa, Nagio Department of Respiratory Medicine, Okayama University Hospital
Chikamori, Kenichi Department of Respiratory Medicine, NHO Yamaguchi-Ube Medical Center
Shibayama, Takuo Department of Medicine, NHO Minami-Okayama Medical Center
Kishino, Daizo Department of Respiratory Medicine, NHO Yamaguchi-Ube Medical Center
Hosokawa, Shinobu Department of Respiratory Medicine, Okayama Red Cross Hospital
Tamaoki, Akihiko Department of Respiratory Medicine, Okayama Institute of Health and Prevention
Harita, Shingo Department of Medicine, Chugoku Central Hospital
Tabata, Masahiro Department of Respiratory Medicine, Okayama University Hospital
Ueoka, Hiroshi Department of Respiratory Medicine, NHO Yamaguchi-Ube Medical Center
Shinkai, Tetsu Department of Respiratory Medicine, NHO Shikoku Cancer Center
Tanimoto, Mitsune Department of Respiratory Medicine, Okayama University Hospital
抄録
Backgrounds: Chemotherapy is a mainstay in the treatment of extensive-disease small-cell lung cancer (ED-SCLC), although the survival benefit remains modest. We conducted a phase II trial of amrubicin (a topoisomerase II inhibitor) and topotecan (a topoisomerase I inhibitor) in chemotherapy-naïve and relapsed SCLC patients. Methods: Amrubicin (35 mg/m(2)) and topotecan (0.75 mg/m(2)) were administered on days 3-5 and 1-5, respectively. The objective response rate (ORR) was set as the primary endpoint, which was assessed separately in chemotherapy-naïve and relapsed cases. Results: Fifty-nine patients were enrolled (chemotherapy-naïve 31, relapsed 28). The ORRs were 74% and 43% in the chemotherapy-naïve and relapsed cases, respectively. Survival data were also promising, with a median progression-free survival time and median survival time of 5.3 and 14.9 months and 4.7 and 10.2 months in the chemotherapy-naïve and relapsed cases, respectively. Even refractory-relapsed cases responded to the treatment favorably (27% ORR). The primary toxicity was myelosuppression with grades 3 or 4 neutropenia in 97% of the patients, which led to grades 3 or 4 febrile neutropenia in 41% of the patients and two toxic deaths. Conclusion: This phase II study showed the favorable efficacy and moderate safety profiles of a topotecan and amrubicin two-drug combination especially in relapsed patients with ED-SCLC.
キーワード
Lung cancer
Topotecan
Amrubicin
Chemo-naive
Sensitive relapse
Refractory relapse
発行日
2011-10
出版物タイトル
Lung Cancer
74巻
1号
出版者
Elsevier Ireland Ltd.
開始ページ
80
終了ページ
84
ISSN
0169-5002
NCID
AA10785743
資料タイプ
学術雑誌論文
言語
English
著作権者
© 2011 Elsevier Ireland Ltd. All rights reserved.
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT